MCID: HYP076
MIFTS: 55

Hyperthyroidism

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hyperthyroidism

MalaCards integrated aliases for Hyperthyroidism:

Name: Hyperthyroidism 12 77 38 30 56 6 44 45 15 17 74
Overactive Thyroid 12 64

Classifications:



External Ids:

Disease Ontology 12 DOID:7998
KEGG 38 H01645
MeSH 45 D006980
NCIt 51 C3123
SNOMED-CT 69 34486009
ICD10 34 E05.9
UMLS 74 C0020550

Summaries for Hyperthyroidism

MedlinePlus : 44 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It is one of your endocrine glands, which make hormones. Thyroid hormones control the rate of many activities in your body. These include how fast you burn calories and how fast your heart beats. All of these activities are your body's metabolism. If your thyroid is too active, it makes more thyroid hormones than your body needs. This is called hyperthyroidism. Hyperthyroidism is more common in women, people with other thyroid problems, and those over 60 years old. Graves' disease, an autoimmune disorder, is the most common cause. Other causes include thyroid nodules, thyroiditis, consuming too much iodine, and taking too much synthetic thyroid hormone. The symptoms can vary from person to person. They may include Being nervous or irritable Mood swings Fatigue or muscle weakness Heat intolerance Trouble sleeping Hand tremors Rapid and irregular heartbeat Frequent bowel movements or diarrhea Weight loss Goiter, which is an enlarged thyroid that may cause the neck to look swollen To diagnose hyperthyroidism, your doctor will do a physical exam, look at your symptoms, and do thyroid tests. Treatment is with medicines, radioiodine therapy, or thyroid surgery. No single treatment works for everyone. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hyperthyroidism, also known as overactive thyroid, is related to graves' disease and thyroid crisis. An important gene associated with Hyperthyroidism is TSHR (Thyroid Stimulating Hormone Receptor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Aldosterone synthesis and secretion. The drugs Propylthiouracil and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, heart and bone, and related phenotypes are Decreased HPV16-GFP infection and homeostasis/metabolism

Disease Ontology : 12 A thyroid gland disease that involves an over production of thyroid hormone.

PubMed Health : 64 About overactive thyroid: The thyroid gland is a part of the body’s endocrine (hormone) system – which is made up of the glands that help regulate many of the body’s different functions. If the thyroid gland is overactive, it produces too much of the thyroid hormone thyroxine. An overactive thyroid (medical term: hyperthyroidism) can be caused by various things. The most common cause is a condition known as Graves disease.The higher levels of thyroid hormones unnecessarily speed up a lot of functions in the body. This can lead to noticeable symptoms such as weight loss, sweating, nervousness or a rapid heartbeat. An overactive thyroid increases the risk of cardiovascular disease (problems affecting the heart and/or blood vessels).If the thyroid gland doesn’t produce enough hormones, the body’s functions slow down. This problem is known as an underactive thyroid or hypothyroidism.

Wikipedia : 77 Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormone by the... more...

Related Diseases for Hyperthyroidism

Diseases in the Hyperthyroidism family:

Familial Hyperthyroidism Due to Mutations in Tsh Receptor

Diseases related to Hyperthyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 graves' disease 33.0 CTLA4 GNAS LMOD1 SERPINA7 TG TPO
2 thyroid crisis 32.7 SERPINA7 TG THRB
3 plummer's disease 32.7 SHBG TG THRB TPO
4 struma ovarii 32.7 TG TSHR
5 myxedema 32.7 CTLA4 TG TPO TSHR
6 nodular goiter 32.6 TG TPO TSHR
7 graves disease 1 32.5 SERPINA7 TG THRB TPO TRH TSHR
8 mccune-albright syndrome 31.7 BGLAP GH1 GNAS PRL SST
9 pituitary tumors 31.7 GH1 GNAS PRL SST
10 multinodular goiter 30.6 GNAS TG TPO TSHR
11 exophthalmos 30.6 PRL TG TSHR
12 hypothyroidism 30.5 CTLA4 GH1 GNAS LEP PRL SERPINA7
13 hashimoto thyroiditis 30.5 CTLA4 TG TPO TSHR
14 thyroid cancer 30.4 BGLAP GNAS SST TG THRB TPO
15 goiter 30.4 BGLAP GNAS SERPINA7 TG THRB TPO
16 goiter, multinodular 1, with or without sertoli-leydig cell tumors 30.4 TG TPO
17 thyroiditis 30.4 CTLA4 SERPINA7 TG THRB TPO TRH
18 papillary carcinoma 30.4 TG TPO TSHR
19 congenital hypothyroidism 30.4 GNAS SERPINA7 TG TPO TSHR
20 primary hyperparathyroidism 30.3 ALPP BGLAP PRL
21 pernicious anemia 30.2 SST TG TPO
22 subacute thyroiditis 30.1 SERPINA6 SERPINA7 SHBG TG TPO TSHR
23 adenoma 30.1 GH1 GNAS PRL SST TSHR
24 diabetes mellitus 30.1 CTLA4 GHRL LEP SHBG SST
25 glucose intolerance 30.1 GHRL LEP SHBG
26 hashimoto encephalopathy 30.0 TPO TSHR
27 benign struma ovarii 30.0 TG TSHR
28 thyroid hormone resistance, generalized, autosomal dominant 30.0 SERPINA7 SHBG TG THRB TRH
29 celiac disease 1 29.9 CTLA4 GHRL TG TPO
30 hypothyroidism, congenital, nongoitrous, 1 29.9 GNAS TSHR
31 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.8 CTLA4 TG TPO TSHR
32 endemic goiter 29.8 SERPINA7 TG TPO TSHR
33 osteoporosis 29.7 ALPP BGLAP GH1 LEP SHBG
34 differentiated thyroid carcinoma 29.7 BGLAP TG TPO TSHR
35 hypoadrenalism 29.6 GH1 SHBG TG
36 chromophobe adenoma 29.6 GH1 PRL SERPINA7 TRH
37 hyperthyroxinemia 29.6 SERPINA7 TPO TRH TSHR
38 thyroid cancer, nonmedullary, 2 29.5 LMOD1 SST TG THRB TPO TSHR
39 anorexia nervosa 29.5 GH1 GHRL LEP PRL
40 conn's syndrome 29.5 GH1 GNAS PRL SST
41 diabetes mellitus, noninsulin-dependent 29.5 GH1 GHRL LEP SHBG SST
42 prolactin producing pituitary tumor 29.4 PRL SST
43 fibrous dysplasia 29.4 BGLAP GH1 GNAS PRL SST
44 nontoxic goiter 29.4 BGLAP SERPINA7 SHBG TG TPO TSHR
45 amenorrhea 29.3 LEP PRL SHBG TRH
46 diabetes mellitus, insulin-dependent 29.3 CTLA4 GHRL SST TG TPO
47 anca-associated vasculitis 29.3 CTLA4 GHRL PRTN3
48 hyperpituitarism 29.2 GH1 PRL SST TRH
49 hyperprolactinemia 29.1 GH1 PRL SHBG SST TRH
50 acromegaly 29.1 GH1 GHRL GNAS PRL SST TRH

Graphical network of the top 20 diseases related to Hyperthyroidism:



Diseases related to Hyperthyroidism

Symptoms & Phenotypes for Hyperthyroidism

GenomeRNAi Phenotypes related to Hyperthyroidism according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased HPV16-GFP infection GR00350-A 8.92 GNAS SDHA SERPINA7 TRH

MGI Mouse Phenotypes related to Hyperthyroidism:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 CTLA4 GHRL GNAS LEP PRL SDHA
2 endocrine/exocrine gland MP:0005379 9.96 CTLA4 GHRL GNAS LEP PRL TG
3 immune system MP:0005387 9.7 CTLA4 GNAS LEP PRL PRTN3 SERPINA6
4 limbs/digits/tail MP:0005371 9.1 GNAS LEP TG THRB TPO TSHR

Drugs & Therapeutics for Hyperthyroidism

PubMedHealth treatment related to Hyperthyroidism: 64

Mild hyperthyroidism sometimes gets better on its own, without treatment. But the overproduction of thyroid hormones is usually first stopped using tablets called anti-thyroid drugs. In Graves disease, long-term treatment with this medication can make the thyroid function return to normal. If that doesn’t happen, the thyroid gland is surgically removed or treated with radioactive iodine. Known as radioiodine therapy, this involves swallowing radioactive iodine which is then absorbed by your thyroid gland, where it destroys overactive cells.If the overactive thyroid is caused by an enlarged thyroid gland with “autonomous” cells, the thyroid gland that has been “slowed down” with anti-thyroid drugs is usually surgically removed. If surgery isn’t possible or the thyroid gland isn’t greatly enlarged, radioiodine therapy tends to be more suitable.

Drugs for Hyperthyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
7
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
8
Methimazole Approved Phase 4,Phase 1,Phase 2,Not Applicable 60-56-0 1349907
9
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7553-56-2 807
10
Parathyroid hormone Approved, Investigational Phase 4,Not Applicable 9002-64-6
11
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
12
Acetylcholine Approved, Investigational Phase 4,Phase 2,Phase 3 51-84-3 187
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1 1177-87-3
15
Cinacalcet Approved Phase 4 226256-56-0 156419
16
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
17
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
18
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
19
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
20
Bimatoprost Approved, Investigational Phase 4,Phase 3,Early Phase 1 155206-00-1 5311027
21
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
22
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
23
leucovorin Approved Phase 4,Not Applicable 58-05-9 143 6006
24
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
25
Methotrexate Approved Phase 4,Not Applicable 1959-05-2, 59-05-2 126941
26
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
27
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
28
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 1406-16-2
30
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
31
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2 41294-56-8 5282181
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
33
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
34 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
37 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
40 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Methylprednisolone Acetate Phase 4,Phase 2,Phase 3,Not Applicable
43 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
48 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
50 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
3 Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol Completed NCT03393728 Phase 4 Propanolol
4 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
5 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
6 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
7 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
8 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
9 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
10 Short-term Prednisone to Treat STA Study(SPTSS) Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
11 99Tc-MDP for Thyroid-Associated Ophthalmopathy Completed NCT03948191 Phase 4 Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
12 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
13 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
14 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
15 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
16 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
17 Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy Recruiting NCT03379181 Phase 4 Propranolol
18 Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy Recruiting NCT01779817 Phase 4
19 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
20 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
21 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
22 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
23 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
24 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
25 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
26 Early Levothyroxine Post Radioactive Iodine Unknown status NCT01950260 Phase 2, Phase 3 Levothyroxine
27 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
28 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
29 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
30 Early Administration of L-carnitine in Hemodialysis Patients Completed NCT00322322 Phase 3 L-Carnitine
31 Low Salt Diet in Idiopathic Hypercalciuria Completed NCT01005082 Phase 2, Phase 3
32 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
33 Antithyroid Drug Treatment of Thyrotoxicosis in Young People Completed NCT01436994 Phase 3 carbimazole;propylthiouracil;thyroxine
34 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
35 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
36 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
37 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
38 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
39 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
40 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Recruiting NCT03725059 Phase 3 Placebo (P);Paclitaxel (X);Doxorubicin hydrochloride (A);Epirubicin (E);Cyclophosphamide (C);Endocrine therapy
41 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
42 Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg
43 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
44 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
45 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Recruiting NCT03635567 Phase 3 Paclitaxel;Cisplatin;Carboplatin;Placebo to pembrolizumab
46 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Active, not recruiting NCT03298867 Phase 3
47 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
48 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
49 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
50 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2

Search NIH Clinical Center for Hyperthyroidism

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyperthyroidism

Genetic Tests for Hyperthyroidism

Genetic tests related to Hyperthyroidism:

# Genetic test Affiliating Genes
1 Hyperthyroidism 30

Anatomical Context for Hyperthyroidism

MalaCards organs/tissues related to Hyperthyroidism:

42
Thyroid, Heart, Bone, Pituitary, Eye, Liver, Testes

Publications for Hyperthyroidism

Articles related to Hyperthyroidism:

(show top 50) (show all 3374)
# Title Authors Year
1
Acute myocardial infarction in pregnancy: spasm caused by hyperthyroidism? ( 30909844 )
2019
2
Local hyperthyroidism promotes pancreatic acinar cell proliferation during acute pancreatitis. ( 30714146 )
2019
3
Toxic nodular goiter and thyroid cancer: Is hyperthyroidism protective against thyroid cancer? ( 31104806 )
2019
4
Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study. ( 30882687 )
2019
5
Euthyroid Graves' disease with spurious hyperthyroidism: a diagnostic challenge. ( 30204589 )
2019
6
Incidence of Neonatal Hyperthyroidism Among Newborns of Graves' Disease Patients Treated with Radioiodine Therapy. ( 30426886 )
2019
7
Hyperthyroidism with Selective Immunoglobulin A Deficiency. ( 30101931 )
2019
8
The Relation Between Epicardial Fat Tissue Thickness and TSH Receptor Antibody in Hyperthyroidism. ( 30107622 )
2019
9
Role of Selenium Intake for Risk and Development of Hyperthyroidism. ( 30265356 )
2019
10
Sexual function and depressive symptoms in men with overt hyperthyroidism. ( 30307028 )
2019
11
Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value. ( 30334140 )
2019
12
Utility of systematic TSHR gene testing in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy. ( 30372544 )
2019
13
Subclinical hyperthyroidism in the course of autonomous nodules - clinical evaluation. ( 30480751 )
2019
14
Rapid Relief: Thyroidectomy is a Quicker Cure than Radioactive Iodine Ablation (RAI) in Patients with Hyperthyroidism. ( 30483883 )
2019
15
Cytomegalovirus reactivation triggers the late onset of hyperthyroidism after autologous peripheral blood transplantation. ( 30533381 )
2019
16
Hyperthyroidism as a late effect in childhood cancer survivors - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study. ( 30585514 )
2019
17
An overlooked aspect in the assessment of systolic pulmonary arterial pressure in female patients with hyperthyroidism. ( 30587712 )
2019
18
Differential effects of hypo- and hyperthyroidism on remodeling of contacts between neurons expressing the neuropeptide EI and tyrosine hydroxylase in hypothalamic areas of the male rat. ( 30590076 )
2019
19
Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. ( 30648498 )
2019
20
Sexual function and depressive symptoms in young women with overt hyperthyroidism. ( 30654201 )
2019
21
Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey. ( 30667296 )
2019
22
Serum zinc-α2-glycoprotein levels are elevated and correlated with thyroid hormone in newly diagnosed hyperthyroidism. ( 30670019 )
2019
23
Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial. ( 30670519 )
2019
24
Long-term outcome of hyperthyroidism diagnosed in childhood and adolescence: a single-centre experience. ( 30685744 )
2019
25
Pattern and Presentation of Thyro-Cardiac Disease among Patients with Hyperthyroidism Attending a Tertiary Hospital in Ethiopia: A Cross Sectional Study. ( 30700956 )
2019
26
Screening of congenital hyperthyroidism in Morocco: a pilot study. ( 30701521 )
2019
27
Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. ( 30719273 )
2019
28
Effects of Preoperative Iodine Administration on Thyroidectomy for Hyperthyroidism: A Systematic Review and Meta-analysis. ( 30721111 )
2019
29
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia. ( 30728680 )
2019
30
IS SEX A PREDICTOR OF OUTCOME OF ANTITHYROID THERAPY OF GRAVES HYPERTHYROIDISM? ( 30742572 )
2019
31
Disruption of the Pituitary Circadian Clock Induced by Hypothyroidism and Hyperthyroidism: Consequences on Daily Pituitary Hormone Expression Profiles. ( 30747053 )
2019
32
Hyperthyroidism Following Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. ( 30769174 )
2019
33
A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy. ( 30800636 )
2019
34
Pesticide use and incident hyperthyroidism in farmers in the Agricultural Health Study. ( 30804163 )
2019
35
Characteristics and outcomes of patients with hyperthyroidism attending a hospital endocrine clinic-A retrospective study. ( 30815574 )
2019
36
Lithium can cause hyperthyroidism as well as hypothyroidism: A systematic review of an under-recognised association. ( 30841715 )
2019
37
Therapeutic plasma exchange and continuous renal replacement therapy for severe hyperthyroidism and multi-organ failure: A case report. ( 30842962 )
2019
38
Insulin resistance and diabetes in hyperthyroidism: a possible role for oxygen and nitrogen reactive species. ( 30843740 )
2019
39
Association of Overt and Subclinical Hyperthyroidism During Weeks 4-8 with Adverse Pregnancy Outcomes. ( 30855205 )
2019
40
One-year study evaluating efficacy of an iodine-restricted diet for the treatment of moderate-to-severe hyperthyroidism in cats. ( 30859084 )
2019
41
MANAGEMENT OF THYROTOXICOSIS AMONG GENERAL PRACTITIONERS IN TRINIDAD COMPARED WITH 2016 AMERICAN THYROID ASSOCIATION GUIDELINES FOR HYPERTHYROIDISM. ( 30865530 )
2019
42
Hyperthyroidism influences renal function. ( 30904999 )
2019
43
The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism. ( 30918165 )
2019
44
Rare and Low-Frequency Variants in RNF213 Confer Susceptibility to Moyamoya Syndrome Associated with Hyperthyroidism. ( 30922903 )
2019
45
Effects of hyperthyroidism in the development of the appendicular skeleton and muscles of zebrafish, with notes on evolutionary developmental pathology (Evo-Devo-Path). ( 30931985 )
2019
46
Hypothyroidism to hyperthyroidism: an immunological pendulum swing from two extreme poles - a case series. ( 30954956 )
2019
47
Acute psychosis in patients with subclinical hyperthyroidism. ( 30968493 )
2019
48
Iatrogenic hyperthyroidism can be a triggering factor for takotsubo cardiomyopathy. ( 30975499 )
2019
49
The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin. ( 30983945 )
2019
50
Serum levels of fetuin-A are negatively associated with log transformation levels of thyroid-stimulating hormone in patients with hyperthyroidism or euthyroidism: An observational study at a medical center in Taiwan: Erratum. ( 30985733 )
2019

Variations for Hyperthyroidism

ClinVar genetic disease variations for Hyperthyroidism:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;X;t(X;3)(p21.3;p25.1)dn Translocation Pathogenic

Expression for Hyperthyroidism

Search GEO for disease gene expression data for Hyperthyroidism.

Pathways for Hyperthyroidism

GO Terms for Hyperthyroidism

Cellular components related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 BGLAP GH1 GHRL LEP PRL PRTN3
2 extracellular region GO:0005576 9.44 BGLAP GH1 GHRL GNAS LEP PRL
3 endosome lumen GO:0031904 9.16 GH1 PRL

Biological processes related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.73 BGLAP GNAS SST
2 female pregnancy GO:0007565 9.7 GNAS LEP PRL
3 positive regulation of multicellular organism growth GO:0040018 9.58 GH1 GHRL TSHR
4 positive regulation of cold-induced thermogenesis GO:0120162 9.56 GHRL GNAS LEP TSHR
5 response to estradiol GO:0032355 9.55 GH1 LEP
6 energy reserve metabolic process GO:0006112 9.54 GNAS LEP
7 response to ethanol GO:0045471 9.54 BGLAP LEP TRH
8 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.51 GH1 PRL
9 positive regulation of JAK-STAT cascade GO:0046427 9.5 GH1 LEP PRL
10 regulation of signaling receptor activity GO:0010469 9.5 GH1 GHRL LEP PRL SST TG
11 hormone biosynthetic process GO:0042446 9.49 TG TPO
12 positive regulation of growth GO:0045927 9.48 GH1 GHRL
13 response to nutrient GO:0007584 9.46 LEP SST
14 hormone-mediated signaling pathway GO:0009755 9.46 GHRL THRB TRH TSHR
15 adult feeding behavior GO:0008343 9.43 GHRL LEP
16 response to nutrient levels GO:0031667 9.02 BGLAP GH1 GHRL LEP PRL

Molecular functions related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 GH1 GHRL LEP PRL SST TG
2 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperthyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....